The steno-2 study: Plea for a global and intensive management of the type 2 diabetic patient;L'étude steno-2: Plaidoyer pour une prise en charge globale et intensive du patient diabétique de type 2

Revue Medicale de Liege

Volumn 58, Issue 2, 2003, Pages 109-111

  Scheen, A J ^a   Estrella, F ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Cardiovascular disease; Dyslipidemia; Hypertension; Microalbuminuria; Prevention; Type 2 diabetes

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; INTENSIVE CARE; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ALBUMINURIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ALBUMINURIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0037239424     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Beckman JA, Creager MA, Libby P. - Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
2. Scheen AJ. - Le syndrome X, à la croisée des maladies métaboliques et cardio-vasculaires. Rev Med Liège, 1998, 53, 29-32.
3. UK Prospective Diabetes Study Group. - Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
4. UK Prospective Diabetes Study Group. - Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J, 1998, 317, 713-721.
5. Kaplan NM. - Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med, 2001, 135, 1079-1083.
6. Gotto AM. - Lipid management in diabetic patients: lessons from prevention trials. Am J Med, 2002, 112 (Suppl 8A), 19S-26S.
7. Heart Protection Study Collaborative Group MRC/BHF. - Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-23.
8. Yki-Järvinen H. - Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs, 2000, 60, 975-983.
9. Scheen AJ, Paquot N. - Le diabète de type 2: approches diagnostiques, objectifs glycémiques et stratégies thérapeutiques. Rev Med Liège, 1999, 54, 659-666.
10. European Study Group. - A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group. Diabetic Med, 1999, 16, 716-730.
11. Halimi S, et groupe de travail de l'AFSSAPS. - Traitement médicamenteux du diabète de type 2. Recommandations: texte long, argumentaire. Diabetes Metab, 1999, 25 (Suppl 6), 1-79.
12. American Diabetes Association. - Standards of medical care for patients with diabetes mellitus. Diabetes Care, 2003, 26 (Suppl 1), S33-S50.
13. Gaede P, Vedel P, Larsen N, et al. - Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-393.
14. Gaede P, Vedel P, Parving HH, et al. - Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet, 1999, 353, 617-622.
15. Solomon CG. - Reducing cardiovascular risk in type 2 diabetes. N Engl J Med, 2003, 348, 457-459.
16. Scheen AJ, Estrella F, Weekers L. - Hypertension artérielle et diabète de type 2. Rev Med Liège, 1999, 54, 789-795.
17. Scheen AJ. - Current management of coexisting obesity and type 2 diabetes. Drugs, 2003, in press.
18. Massi-Benedetti M (Ed). - The cost of diabetes type II in Europe. The CODE-2 study. Diabetologia, 2002, 45 (Suppl 1), S1-S28.